医学
缬沙坦
肌酐
硝苯地平
肾功能
内科学
糖尿病肾病
血压
内分泌学
血尿素氮
泌尿科
沙库比林
肾病
沙库比林、缬沙坦
药理学
糖尿病
钙
作者
Yinyu Wei,Liu Hu,Guoying Liu
标识
DOI:10.1016/j.intimp.2023.110755
摘要
This study aimed to evaluate the efficacy of nifedipine controlled-release tablets combined with sacubitril valsartan in diabetic nephropathy (DN) patients with hypertension. One hundred and twelve DN patients with hypertension were enrolled. They were randomly divided into the control group (treated with nifedipine controlled-release tablets combined with valsartan) and the observation group (treated with nifedipine controlled-release tablets combined with sacubitril valsartan). Renal function, endothelial function and inflammatory response were examined. After three-months treatment, the levels of clinical indexes (glycosylated hemoglobin, fasting blood glucose, systolic and diastolic blood pressure), renal function indicators (urinary albumin excretion rate, blood urea nitrogen, serum creatinine and cystatin C), endothelial function indicators (microalbumin, angiotensin II, thrombomodulin and cartilage oligomeric matrix protein) and inflammatory response factors (interleukin-6 and tumor necrosis factor-α) in the observation group were significantly lower than those in the control group. Nifedipine controlled-release tablets combined with sacubitril valsartan could effectively alleviate the progression of DN combined with hypertension.
科研通智能强力驱动
Strongly Powered by AbleSci AI